ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ARMP vs OTLK // OPERATING MARGIN

Armata Pharmaceuticals Inc. (NYSE) VS. Outlook Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ARMP 2 — OTLK 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARMP VS. OTLK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ARMP OTLK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 4.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -21.77% — — TIE /fcf-yield <GO>
Operating Margin ACTIVE — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.8 37.0 +6.83 ARMP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $120.8M $120.1M $700.1K ARMP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ARMP REV OTLK REV ARMP GROSS % OTLK GROSS % ARMP FCF OTLK FCF
FY 2025 $0 $1.4M — 4.0% -$26.3M -$51.8M
FY 2024 $0 $0 — — -$39.4M -$68.8M
FY 2023 $0 $0 — — -$47.4M -$43.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARMP // BETA —
OTLK // BETA —